Gastrointestinal Cancer | Specialty

Neoadjuvant/Adjuvant Approaches in Colorectal Cancer

February 10th 2017

Curative Intent in Oligometastatic Colorectal Cancer

February 10th 2017

MSI Status and Immunotherapy in Advanced Colorectal Cancer

February 10th 2017

Antibody Selection and Right- Versus Left-Sided Colorectal Cancer

February 10th 2017

Understanding Tumor Sidedness in Colorectal Cancer

February 10th 2017

ADI-PEG 20 Added to Standard Therapy Shows Potential Promise in Pancreatic Cancer

February 10th 2017

The addition of ADI-PEG 20, a pegylated form of an arginine-depleting enzyme, to nab-paclitaxel and gemcitabine showed encouraging activity and minimal additional toxicity in the treatment of patients with advanced pancreatic adenocarcinoma.

Dr. Loaiza-Bonilla on Trial of Left- and Right-Sided Colorectal Cancer

February 9th 2017

Arturo Loaiza-Bonilla, MD, medical oncologist, specializing in gastrointestinal malignancies, assistant professor of Clinical Medicine at the University of Pennsylvania, discusses a clinical trial focused on the differences between left- and right-sided tumors of colorectal cancer (CRC).

Expert Discusses PD-1 Success in MSI-H Colorectal Cancer

February 9th 2017

Michael J. Overman, MD, discusses the significance of the ongoing CheckMate-142 study and the next steps in microsatellite instability-high metastatic colorectal cancer.

Dr. Ku on Immunotherapy in Gastric and Esophageal Cancer

February 9th 2017

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

Analysis Confirms Survival Benefit With Nanoliposomal Irinotecan Regimen in Pancreatic Cancer

February 7th 2017

Patients with metastatic pancreatic ductal adenocarcinoma lived longer and had slowing of disease progression when nanoliposomal irinotecan was added to 5-fluorouracil and leucovorin, irrespective of treatment history, a posthoc analysis of a randomized trial showed.

Atezolizumab/Bevacizumab Combo Attains 90% DCR in MSI-High mCRC

February 7th 2017

Patients with microsatellite-high metastatic colorectal cancer responded to an immunotherapy-containing regimen, according to results of a preliminary clinical evaluation presented at the 2017 Gastrointestinal Cancers Symposium.

Little Correlation Between Phase II, III Trials in Advanced Pancreatic Cancer

February 7th 2017

Few phase II trials in advanced pancreatic cancer conformed to recommended design characteristics for pilot trials, a contributing factor to lack of success in the disease, Australian investigators reported.

Napabucasin Linked With Objective Responses in Advanced CRC

February 7th 2017

As many as one-third of patients with treatment-resistant colorectal cancer attained objective responses with the stemness inhibitor napabucasin plus FOLFIRI chemotherapy with or without bevacizumab, according to evaluable results of a study presented at the 2017 Gastrointestinal Cancers Symposium.

Dr. Sears on Bacteria Influencing Development of Colon Cancer

February 7th 2017

Cynthia L. Sears, MD, professor of Medicine, Johns Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses bacteria possibly influencing the development of colon cancer.

Enhanced Recovery Program Improves Outcomes After Colorectal Cancer Surgery

February 3rd 2017

The adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.

Dr. Muro Discusses Safety Data from Asian XELIRI Project in CRC

February 2nd 2017

Kei Muro, MD, Aichi Cancer Center Hospital, discusses the findings of Asian XELIRI project (AXEPT) in colorectal cancer (CRC).

S-1 Better Tolerated Than Capecitabine With No Loss of Efficacy in Metastatic Colorectal Cancer

February 2nd 2017

The incidence of hand-foot syndrome was decreased following first-line treatment with S-1 compared to capecitabine in patients with metastatic colorectal cancer, according to findings from the phase III SALTO study that were presented at the 2017 European Cancer Congress.

Treatment, Diagnosis Disparities Among Hospitals Impacts Survival of Patients With Colorectal Cancer and Peritoneal Metastases

February 1st 2017

Patients receiving the same diagnosis, colorectal cancer with synchronous peritoneal metastases, were offered different treatments that led to dramatically different outcomes based upon the institution in which they were diagnosed. Findings presented at the 19th European Cancer Congress revealed underutilization of a highly effective treatment, due to a lack of referral.

PD-1 Inhibitor Active in Advanced Liver Cancer

February 1st 2017

Patients with advanced hepatocellular carcinoma had objective responses and prolonged survival when treated with single-agent nivolumab, data from a dose escalation/expansion trial showed.

Dr. Lin on Chemoradiation in Elderly Patients with Esophageal Cancer

February 1st 2017

Steven H. Lin, MD, PhD, associate professor at The University of Texas MD Anderson Center, discusses study of chemoradiation in elderly patients with esophageal cancer.